Donate
My Journey to Eli Lilly HQ for Answers

My Journey to Eli Lilly HQ for Answers

Facebook Google LinkedIn Twitter

I was very nervous before going to confront the top executives of Eli Lilly and Company. But I was determined to tell them Alec’s story. They needed to hear from me what their insulin prices did to Alec, and are still doing to others.

The morning of May 7th, I and supporters from T1InternationalKOIinsulin4all and People of Faith for Access to Medicines arrived at the sidewalk in front of the Eli Lilly global headquarters in Indianapolis, Indiana. I had a ticket to the company’s annual shareholder’s meeting at 11AM, but I spent more than an hour beforehand being interviewed by several different reporters for TV and radio. I also read a statement to the entire group, with all of it live-streamed on T1International’s Facebook page.

Then, I was ushered into the shareholder meeting by several Lilly staff members, led by their USA Diabetes director, company vice president Mike Mason. The meeting was very scripted and formal and there were probably less than 100 people there. The media and most of the supporters who joined me were not allowed in. There was a time in the meeting set aside for Q and A—but no one was allowed to stand up and ask questions directly to the company CEO, Dave Ricks. So I submitted three questions in writing.

My three questions were:

  • Does Eli Lilly consider insulin access to be a human right?
  • What is Eli Lilly doing about insulin affordability?
  • Why has the price of insulin gone up so much in the last 20 years when the formula has stayed the same?

My questions were read to CEO Ricks. He really did not answer them, especially the justification for the huge price increases. He referenced the company’s patient assistance programs but admitted, “There is more we can do.” And he said, “We realize there is frustration with this. We are frustrated.” He claimed that most patients have access to insulin at a cost to them of under $50 a month. “But there are exceptions,” he said.

Is that what Alec was to them? One of the exceptions?

The shareholder meeting lasted less than an hour. Immediately afterward, I was brought to a room for a face-to-face meeting with Mike Mason and two other Lilly staff members. They were very polite and expressed sympathy for me and my family and sadness about what happened to Alec. I appreciated that, but I was not there to receive kind words.

I read my statement to them (you can see the full copy here). I cried a few times, of course, especially at the end. But I was determined to get through it. And I did not hold anything back. One of the things I said was this: “On Alec’s death certificate, the official cause of death is listed as DKA—Diabetic Ketoacidosis. But the unofficial cause of death is slipping through the cracks of our broken health care system—and corporate greed.” 

When I said that, I made sure to look Mr. Mason in the eye when I said the words, “Corporate greed.”

Here is what I said to them about the hypocrisy I saw on their website:

Your Mission: You report that your mission is ‘to make medicines that help people live longer, healthier, more active lives’. My son’s life was cut short because your insulin cost too much. Your insulin pricing cost him his life!!

Your Values: Your values are ‘integrity, excellence and respect for people’. Your greed for profits currently outweighs your respect for human life. When will you start living up to your values?

Your Promise: Your promise is to ‘unite caring with discovery to make life better for people around the world’. How are you making life better if people are dying because they cannot afford the cost of your decades-old insulin products?

When I was finished reading the statement, I was pretty broken up. But I pulled myself together and took out a photo of Alec—his high school graduation photo. I held it in front of them and said, “This is my Alec. This is my baby.”

I don’t think they intended to talk with me about how to fix things. But that is what I was there for. Mr. Mason said he would share my and Alec’s story with his team, and he said I had his commitment to internalize this and to do better. I wiped my tears and looked straight at him. “So what does that look like?” I demanded.

He talked a little about their patient assistance programs and I told him how they did not work for so many people. (I never dreamed I would become an expert on insulin pricing and programs, but that is what has happened to me this past year . . .) They said they promote their programs, but I pointed out how they don’t spend a fraction of the money promoting their programs as they do advertising their drugs.

There was mention of the complex health care system in the U.S. I acknowledged that, but I said, “To my mind, it all starts with the list price.”

As we wrapped up, I repeated to them that I and other advocates will not stop until insulin and other essential medicines are available to all. I asked for Mr. Mason’s contact information and made him promise to personally follow up with me. You better believe that, in Alec’s memory, I will hold him to it.

Related posts:

T1International and #insulin4all Advocates Score Major Win

T1International and #insulin4all Advocates Score Major Win

Following years of advocacy on affordable insulin for T1International, today Eli Lilly announced that vials of generic insulin Lispro will be available to all US customers for $25 effective May 1, 2023. Some other Eli Lilly insulins will also be made more affordable by the end of the year. Current list prices for insulin can be over $300 per vial. Read more

#insulin4all Workshop & Vigil

#insulin4all Workshop & Vigil

In September 2019, T1International held our first ever two-day #insulin4all workshop for USA Chapters. The purpose of the workshop was to bring Chapter Leaders together and build their skills and advocating power to push for more affordable, accessible insulin and supplies. About 45 people from about 20 Chapters across the USA came to Indianapolis for the workshop, which included a third annual event outside of Eli Lilly taking the form of a vigil to honor lives lost due to rationing. Read more

Losing Andy to America’s Unkind Healthcare System

Losing Andy to America’s Unkind Healthcare System

Andy was quiet but he was always willing to help people. He would give you the shirt of your back if you needed it. I wish that America’s healthcare system was more like Andy, treating everyone with kindness instead of forcing people to go to Canada or go on the black market to get what they need. Read more

Our Jesy, Gone Too Soon

Our Jesy, Gone Too Soon

The only reason Jesy did not have his insulin – a life dependent drug – was because he couldn’t afford it. He wasn’t lazy. He worked hard, even taking on a second job for some time. Unlike some of the other stories I have heard, Jesy had insurance but the insulin and other supplies were still more than he could afford. The month Jesy died there were four known deaths due to insulin rationing. How many unknown deaths were there? How many deaths will we continue to see before changes are made? Read more

Josh Died Because His Insulin Cost Too Much

Josh Died Because His Insulin Cost Too Much

People in the United States of America are dying from type 1 diabetes. For many people, the cost for life saving medications each month is the same as an average months’ rent - or more. How is an average American to afford this? When it comes to type 1 diabetes, people are facing unthinkable decisions – between the costs of living and their very lives – because they live with a non-preventable disease. Read more

Honoring Antavia as I Fight for Affordable Insulin

Honoring Antavia as I Fight for Affordable Insulin

I hope Antavia’s story will touch the hearts of the pharmaceutical companies, Congress, and everyone who can help ensure that insulin is affordable to the American people. Living with type 1 diabetes like other chronic illnesses is unaffordable, which forces people into situations where they become noncompliant with managing their care. I hope one day insulin will be as affordable as it is in other high-income countries, and I am glad to add my voice and Antavia’s story to the #insulin4all movement. Read more

My Sister Jada Should Never Have Died

My Sister Jada Should Never Have Died

At 24 years old, Jada was supposed to have more time. She was supposed to be the maid of honor at her best friend’s wedding. She was supposed to lead the drama ministry at church. She was supposed to give me a niece or nephew a few years down the line. But having no insurance and plenty of bills to pay, my sister was forced to make a choice that would take all of that away from her. Read more

Novo Nordisk Meeting: 2 Executives, 2 Doctors, 1 Patient

Novo Nordisk Meeting: 2 Executives, 2 Doctors, 1 Patient

Although Lars said that he is “Not shying away from anything that costs money,” it was clear that he was not going to lower the list price. I’m not holding my breath and we, the diabetes community, are not going to wait. Only legislation will ensure insulin is truly accessible and affordable for all. We will not stop until that is the reality because our lives depend on it. Read more

Remembering Jesse in the Fight for #insulin4all

Remembering Jesse in the Fight for #insulin4all

On February 7, 2018, 32-year-old Jesse Lutgen passed away. He lost his job and health insurance the November prior to his death, and he did not qualify for Medicaid. The least expensive insurance plan he could enrol in had a $10,000 deductible. Jesse received his last vials of insulin from a family friend. Read more

Losing Rachel, Our Only Daughter

Losing Rachel, Our Only Daughter

More education is needed in our homes, schools, and with our doctors. I have learned that living in a rural area, awareness and education about type 1 diabetes and its symptoms are even less known and understood. Access to specialists in rural areas can be limited, which makes it even more likely that type 1 diabetes will go undiagnosed. I share Rachel’s story to educate others so that this doesn’t happen to another family. Read more

Reminder: Eli Lilly Has Been Exploiting T1Ds Since 1922

Reminder: Eli Lilly Has Been Exploiting T1Ds Since 1922

The “business of diabetes” did not spontaneously emerge mid-century. Corporate stakeholders found underhanded ways to profit from diabetic lives before most affected individuals had even obtained their first injection. And now that Congress is investigating insulin manufacturers, it is important to acknowledge the full scope of their involvement. Read more

T1International Statement on Lilly & Novo's ''Generic Insulin''

T1International Statement on Lilly & Novo's ''Generic Insulin''

Patient-led activism is working. Today Eli Lilly announced that in response to criticism of high prices, the company will sell a version of Humalog insulin for half price. We are pleased to see this result after continual and dedicated efforts by non-pharma funded patient advocates to ensure list price of insulin goes down. While half-price is an improvement, it's still an unaffordable price for so many, considering most people need at least 2 vials each month.
Read more

Hoosiers with Diabetes Petition Indiana General Assembly to Study Drug Pricing

Hoosiers with Diabetes Petition Indiana General Assembly to Study Drug Pricing

Hoosiers living with Type 1 diabetes today delivered to the Indiana General Assembly a petition signed by over 500 persons demanding that the House Public Health Committee hear a bill to establish a study committee on rising prescription drug prices. The petition was delivered to House of Representatives Public Health Committee Chair Rep. Cindy Kirchofer and all of the committee members. Read more

T1International Names Nicole Smith-Holt Ambassador

T1International Names Nicole Smith-Holt Ambassador

T1International is proud and honoured to announce that Nicole Smith-Holt as accepted our invitation to serve as T1International Charity Ambassador. Read more

Standing Up For My Daughter at Eli Lilly

Standing Up For My Daughter at Eli Lilly

I am not normally an angry or bitter person, but I am a mother who will fight for her children to the end. It infuriates me to tears to think that my child, or anyone’s child, has to pay extortionate prices for a medication that keeps them alive, especially a medication that is very inexpensive to manufacture. Read more

Raising My Voice at Eli Lilly

Raising My Voice at Eli Lilly

The whole experience of the demonstration showed me that I am not alone. My voice was heard. My daughter said throughout the day that she met great people. She also networked and built relationships with others who are supporting family members or close friends with diabetes, just as she supports me, and it showed her that we are all going through this battle together. We all have voices that matter. Read more

Why I Protest to Fight for #insulin4all

Why I Protest to Fight for #insulin4all

I could not be more pleased with my experience at last year’s #insulin4all demonstration. I met so many wonderful advocates who joined me in asking for insulin pricing transparency. I now consider many of them close friends. Because of my participation I am now part of KOI#insulin4all, a grassroots volunteer advocacy group asking for insulin pricing transparency in Kentucky, Ohio, and Indiana. What began last year as a “Should I go?” this year has become “I wouldn’t miss it!”. I invite you to join us this year in taking a stand. Read more

Taking a Stand at Eli Lilly Headquarters

Taking a Stand at Eli Lilly Headquarters

I joined dozens of people impacted by the rising cost of insulin in the USA in protest of those prices in front of Eli Lilly headquarters in Indianapolis, Indiana. Some had traveled many hours to join the protest, but one thing was made clear, we wanted to ensure that Eli Lilly heard our voices. We were passionate in our outcry for change and jointly understood that not saying anything is simply not an option.
Read more

Patients vs. Pharma: Hagens Berman files complaint against 'Big Three' insulin producers

Patients vs. Pharma: Hagens Berman files complaint against 'Big Three' insulin producers

The law firm Hagens Berman has filed a complaint against Eli Lilly, Novo Nordisk, and Sanofi, the ‘big three’ pharmaceutical companies that hold a near-monopoly on the insulin market. People living with type 1 diabetes will be the plaintiffs in this class action lawsuit, which alleges that Eli Lilly, Novo Nordisk and Sanofi have unjustly inflated their prices. Read more

Eli Lilly and Novo Nordisk: More Empty Promises

Eli Lilly and Novo Nordisk: More Empty Promises

Outrage at soaring insulin prices in the USA has been increasing. More patients and families are speaking out against unaffordable costs for life-saving medication than ever before. In response, two of the 'Big Three' insulin makers (who control over 90% of the insulin market) have recently made moves to combat this anger. Read more